The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...
Apparently doctors aren't quite as easily manipulated by pharma as we all thought. Despite a vigorous marketing effort, Bidil was seen by cardiologist as what it is- an expensive combination of two generics and was not used- even after insurance companies started to pay for it.
My expertise in the clinical research of Torcetrapib and reports presented at the latest American College of Cardiology meetings made me conclude that the failure of Torcetrapib in rendering clinical benefits were related to intrinsic problems of the drug which effected the nature of the HDL which...
Those like myself who have more extensive knowledge on the rational used by the FDA to reject the approval of Rimonabant and know the differences between Rimonabant and Taranabant do not believe that there is an error in judgment by Merck in developing their new cannabinoid receptor antagonist. This...
The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant. The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...
Merck and Schering Plough has finally released the ENHANCE trial. The results were bad- and the cover up was worse. Those who predict no fall out from this study are kidding themselves.
Physicians have several possible conclusions that can be taken; These include:
- the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study
- the failure to meet the trial endpoint is only a surrogate and clinical trial data...
Diabesity is pandemic, too late diagnosed, too little treated. ADA recommendations for screening with fasting blood sugars result in relatively late diagnoses since the FBS doesn't usually rise until the disease has been present for several years.
Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.
This makes it easier for me to avoid mention or suggestion to my patients to try glitazones. I am having an easier time now with prior approvals of Januvia after only a trial of Metformin and sulfonylureas